Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Nucleosome accessibility in CUTLL3 cell line treated with Vehicle or Pitavastatin and 3 ETP-ALL patients

ABSTRACT: Nucleosome accessibility in CUTLL3 cell line treated with Vehicle or Pitavastatin and 3 ETP-ALL patients

PROVIDER: PRJNA692468 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13444339_1.fastq.gz	Fastqsanger.gz
	SRR13444339_2.fastq.gz	Fastqsanger.gz
	SRR13444340_1.fastq.gz	Fastqsanger.gz
	SRR13444340_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Nucleosome accessibility in CUTLL3 cell line treated with Vehicle or Pitavastatin and 3 ETP-ALL patients

Project description:Analysis of nucleosome accessibility in CUTLL3 ETP-ALL cells following treatment with Vehicle or Pitavastatin for 48 hours and ETP-ALL patients at diagnosis

2021-10-21 | GSE164931 | GEO

H3K27acetylation ChIP-seq in CUTLL3 cell line treated with Vehicle or Pitavastatin

Project description:Analysis of H3K27Ac in CUTLL3 ETP-ALL cells following treatment with Vehicle or Pitavastatin for 48 hours

2021-10-21 | GSE164930 | GEO

RNA-seq in CUTLL3 cell line treated with Vehicle or Pitavastatin

Project description:Analysis of RNA-seq gene expression signatures in CUTLL3 ETP-ALL cells following treatment with Vehicle or Pitavastatin for 48 hours

2021-10-21 | GSE164929 | GEO

RNA-seq in CUTLL3 cell line treated with Vehicle or Pitavastatin

Project description:RNA-seq in CUTLL3 cell line treated with Vehicle or Pitavastatin

| PRJNA692465 | ENA

H3K27acetylation ChIP-seq in CUTLL3 cell line treated with Vehicle or Pitavastatin

Project description:H3K27acetylation ChIP-seq in CUTLL3 cell line treated with Vehicle or Pitavastatin

| PRJNA692467 | ENA

Combined pitavastatin and capmatinib inhibits tumor growth though completed shutdown of MET signal

Project description:To reveal the function of pitavastatin in cancer, we performed several experiments. In the present study, we show that pitavastatin inhibits the tumor growth through the inactivation of ERK and AKT signals by MET immaturation, and combination of pitavastatin and capmatinib, a MET inhibitor, might be useful cancer therapy in OSCC and ESCC. It could be reduced the dose of pitavastatin by using this combination therapy, resulting in decreasing the risk of adverse events such as myopathy. Taken together, the mevalonate pathway regulates the processes of MET maturation and promotes the cell growth in cancer. Moreover, the expression of GGPS1, an enzyme that synthesizes geranylgeranyl pyrophosphate (GGPP) from farnesyl pyrophosphate (FPP), associates with the sensitivity of pitavastatin, suggesting that GGPS1 could be a biomarker in cancer therapy with pitavastatin. Identification of the function of pitavastatin in oral and esophageal squamous cell carcinoma.

2021-02-19 | GSE145624 | GEO

Widespread changes in nucleosome accessibility without changes in nucleosome occupancy during a rapid transcriptional induction

Project description:Activation of transcription requires alteration of chromatin by complexes that increase the accessibility of nucleosomal DNA. Removing nucleosomes from regulatory sequences has been proposed to play a significant role in activation. We tested whether changes in nucleosome occupancy occurred on the set of genes that are activated by the unfolded protein response (UPR). We observed no decrease in occupancy on most promoters, gene bodies, and enhancers. Instead there was an increase in the accessibility of nucleosomes, as measured by MNase digestion and by ATAC-seq, that did not result from removal of the nucleosome. Thus changes in nucleosome accessibility predominate over changes in nucleosome occupancy during rapid transcriptional induction during the UPR.

2017-06-06 | GSE95689 | GEO

MNase titration reveals differences between nucleosome occupancy and chromatin accessibility

Project description:Chromatin accessibility plays a fundamental role in gene regulation. One mechanism to regulate accessibility is nucleosome placement, which is often measured by quantifying protection of DNA from enzymatic digestion. We introduce a metric that uses micrococcal nuclease (MNase) digestion in a novel manner to measure chromatin accessibility by combining information from several digests of increasing depths. This metric, MACC, quantifies the inherent heterogeneity of nucleosome accessibility in which some nucleosomes are seen preferentially at high MNase and some at low MNase. MACC interrogates each genomic locus, measuring both location of nucleosomes and accessibility to MNase in the same assay. MACC can be performed either with or without a histone immunoprecipitation step, and thereby compares behavior of nucleosomes to that of non-histone proteins. We find that enhancers, promoters and other regulatory regions have changes in accessibility that do not correlate with changes in nucleosome occupancy. Moreover, we show that high nucleosome occupancy does not necessarily preclude high accessibility, revealing novel principles of chromatin regulation.

2016-04-18 | GSE78984 | GEO

mRNA expression profile in HeLa cells that subject to pitavastatin treantment.

Project description:mRNA expression profiles were compared between treatment of pitavastatin or not in the presence or absence of a Sendai virus infection.

2023-03-29 | GSE199783 | GEO

Metabolic profiling of ETP-ALL

Project description:Metabolic profiling of ETP-ALL

| PRJNA692461 | ENA